{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:23:26Z","timestamp":1792189406306,"version":"4.4.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"DOI":"10.1097\/qai.0b013e3181ff63ee","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T08:07:43Z","timestamp":1294214863000},"page":"222-229","source":"Crossref","is-referenced-by-count":22,"title":["Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)"],"prefix":"10.1097","volume":"56","author":[{"given":"Paul M","family":"McNicholas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Wojcik","family":"BSc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping Qiu","family":"PhD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M","family":"Strizki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210131","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.17.1.657","article-title":"Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.","volume":"17","author":"Berger","year":"1999","journal-title":"Ann Rev Immunol"},{"key":"R2-4-20210131","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 Activity.","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-4-20210131","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/mol.107.042101","article-title":"Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.","volume":"73","author":"Kondru","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R4-4-20210131","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","article-title":"Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.","volume":"49","author":"Strizki","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-4-20210131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2006.11.004","article-title":"HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.","volume":"361","author":"Pugach","year":"2007","journal-title":"Virology"},{"key":"R6-4-20210131","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.","volume":"81","author":"Westby","year":"2007","journal-title":"J Virol"},{"key":"R7-4-20210131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.virol.2007.12.009","article-title":"Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.","volume":"373","author":"Ogert","year":"2008","journal-title":"Virology"},{"key":"R8-4-20210131","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/652189","article-title":"Characterization of emergent HIV resistance in treatment naive subjects enrolled in a vicriviroc phase 2 trial.","volume":"201","author":"McNicholas","year":"2010","journal-title":"J Infect Dis"},{"key":"R9-4-20210131","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/650342","article-title":"Vicriviroc in combination therapy with an optimized regimen for treatment experienced subjects: 48 week results of the VICTOR-E1 phase 2 trial.","volume":"201","author":"Suleiman","year":"2010","journal-title":"J Infect Dis"},{"key":"R10-4-20210131","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1128\/JVI.00444-08","article-title":"In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.","volume":"82","author":"Tsibris","year":"2008","journal-title":"J Virol"},{"key":"R11-4-20210131","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1086\/592052","article-title":"Phase II study of vicriviroc versus efavirenz (both with zidovudine\/lamivudine) in treatment-naive subjects with HIV-1 infection.","volume":"198","author":"Landovitz","year":"2008","journal-title":"J Infect Dis"},{"key":"R12-4-20210131","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.1073\/pnas.221375398","article-title":"SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-infection in vitro and in vivo.","volume":"98","author":"Strizki","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-4-20210131","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350701200709","article-title":"Predicting HIV coreceptor usage on the basis of genetic and clinical covariates.","volume":"12","author":"Sing","year":"2007","journal-title":"Antivir Ther"},{"key":"R14-4-20210131","doi-asserted-by":"crossref","first-page":"13376","DOI":"10.1128\/JVI.77.24.13376-13388.2003","article-title":"Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.","volume":"77","author":"Jensen","year":"2003","journal-title":"J Virol"},{"key":"R15-4-20210131","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.","volume":"51","author":"Whitcomb","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-4-20210131","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.","volume":"80","author":"Westby","year":"2006","journal-title":"J Virol"},{"key":"R17-4-20210131","first-page":"94","article-title":"An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies.","volume":"3","author":"Reeves","year":"2009","journal-title":"J Viral Entry"},{"key":"R18-4-20210131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.virol.2010.01.037","article-title":"Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.","volume":"400","author":"Ogert","year":"2010","journal-title":"Virology"},{"key":"R19-4-20210131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QAI.0b013e3181989a8b","article-title":"Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.","volume":"50","author":"Goetz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-4-20210131","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1073\/pnas.0811713106","article-title":"Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.","volume":"106","author":"Cleo","year":"2009","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201103010-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:49:07Z","timestamp":1786042147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201103010-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181ff63ee","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7970956.8338054","asserted-by":"object"}]},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}